2,742 reports of this reaction
2.4% of all LETROZOLE TABLETS reports
#8 most reported adverse reaction
ALOPECIA is the #8 most commonly reported adverse reaction for LETROZOLE TABLETS, manufactured by Avet Pharmaceuticals Inc.. There are 2,742 FDA adverse event reports linking LETROZOLE TABLETS to ALOPECIA. This represents approximately 2.4% of all 116,600 adverse event reports for this drug.
Patients taking LETROZOLE TABLETS who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is a less commonly reported adverse event for LETROZOLE TABLETS, but still significant enough to appear in the safety profile.
In addition to alopecia, the following adverse reactions have been reported for LETROZOLE TABLETS:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 2,742 FDA reports for LETROZOLE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 2.4% of all adverse event reports for LETROZOLE TABLETS, making it a notable side effect.
If you experience alopecia while taking LETROZOLE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.